Breast Cancer Therapeutics Market size was valued at USD 30.22 billion in 2022 and is expected to reach at USD 79.77 billion by 2030, and grow at a CAGR of 12.9% over the forecast period of 2023-2030.
Breast cancer is a type of cancer that develops in the cells of the breasts. Breast cancer therapy refers to the many treatments available for breast cancer. The stage and kind of breast cancer, the presence of hormone receptors, the patient's general health, and personal preferences all affect the therapy option. Breast cancer medicines include a selection of therapies designed to fight the cancer that develops in the breast tissue, breast cancer. These treatments aim to get rid of cancer cells, stop their growth and spread, and enhance the patient's prognosis as a whole. Here is a summary of the most common breast cancer treatments
Breast cancer treatment primarily involves surgery. The sort of surgery carried out is determined by the tumour’s size, stage, and the patient's preferences. In a lumpectomy, also referred to as breast-conserving surgery, the tumour and a tiny portion of the surrounding healthy tissue are removed. The entire breast tissue must be removed after a mastectomy, with or without breast reconstruction. The stage and characteristics of the malignancy, molecular profiling, patient preferences, and general health all have a role in the choice and order of therapies. Treatment strategies are frequently customised for each patient, and the best therapeutic strategy is chosen in consultation with a diverse team of medical experts. Our understanding of breast cancer therapies continues to grow thanks to ongoing research and clinical trials. In order to choose the best course of treatment for their unique situation, individuals must speak with their healthcare providers.
Drivers :
Rising clinical trials for the Breast Cancer Therapeutics Market
Clinical trials are essential for developing new treatments for breast cancer. These studies assess the efficacy and safety of novel therapy strategies, medication combinations, and other medical interventions. To assist regulatory approvals and direct clinical practise, they offer useful data. Clinical trials also give researchers the chance to pinpoint patient groups that could benefit from particular therapies.
Restrain
Inequalities in access to breast cancer therapies continue to be problematic, especially for underserved and low-income groups.
Opportunity
Rise in the technological advancement in the healthcare sector specially related to the imaging sector.
Breast cancer can now be identified earlier and with greater accuracy thanks to improvements in imaging technology and diagnostic equipment. The ability to better characterise tumours using methods like mammography, MRI, and molecular profiling facilitates the choice of the most effective therapeutic strategies. The idea of personalised medicine has become more popular in the treatment of breast cancer. It entails creating treatment regimens that are specific to each patient's tumour and their individual characteristics. The molecular profile of tumours, which includes information on HER2 expression, hormone receptor status, and genetic alterations, aids in therapeutic decision-making and identifies patients who might benefit from particular targeted medicines.
Challenge
Chemotherapy and radiation therapy are two common breast cancer therapies that can have serious side effects that lower a patient's quality of life.
Healthcare infrastructure in Ukraine has been damaged and disrupted as a result of the war, particularly in places where fighting has taken place. Limited access to breast cancer detection and treatment services may be the result of hospitals, clinics, and cancer treatment facilities being damaged or forced to close. Delays in diagnosis, the start of treatment, and follow-up care may result from this. As a result of the war, a large number of individuals have been compelled to from their homes and seek safety in other regions of Ukraine or neighbouring countries. Accessing healthcare services, such as breast cancer screening, diagnosis, and treatment, can be difficult for people who have been displaced. The results of treatment can be negatively impacted by interruptions in continuity of care.
Impact of Recession :
The price of medical services and prescription drugs may rise during recessionary times as well. Patients and healthcare systems may be financially burdened by breast cancer therapies' escalating costs. This may restrict access to more advanced, pricey treatments and may have an effect on treatment selection and adherence. Clinical trial execution may be impacted by budgetary restrictions brought on by the recession. Clinical trial efforts may be reduced or delayed by pharmaceutical corporations and research organisations, which could have an impact on the development and assessment of novel breast cancer medicines. Clinical trial delays may extend the time until novel therapies are available while reducing patient options.
By Therapy Type
Targeted Therapy
Hormonal Therapy
Chemotherapy
Immunotherapy
By Cancer Type
Hormone Receptor
HER2+
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
.png)
North America will be the region which has the highest growth rate because of The healthcare systems in North America, especially in the United States, are well-developed, and there is access to cutting-edge breast cancer therapies. Numerous people employ personalised medicine, targeted treatments, and immunotherapies. Research efforts and clinical trials play a significant role in the creation of novel therapy alternatives.
Europe will be the region with the second largest share because majority of European nations have developed healthcare systems with access to a variety of breast cancer treatments.
Due to differences in healthcare finance models and reimbursement policies, treatment methods and access to certain therapies may vary throughout nations. Comprehensive cancer registries exist in a number of European nations, which helps with research and surveillance initiatives.
The major key players are Pfizer, Eli Lilly and Company, Novartis Ag, Sanofi, Eisai Co., Merck & Co, Bristol Myers Squibb, AstraZeneca, Kyowa Kirin and others.
| Report Attributes | Details |
| Market Size in 2022 | US$ 30.22 Bn |
| Market Size by 2030 | US$ 79.77 Bn |
| CAGR | CAGR of 12.9 % From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Therapy Type (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy) • By Cancer Type (Hormone Receptor, HER2+) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Pfizer, Eli Lilly and Company, Novartis Ag, Sanofi, Eisai Co., Merck & Co, Bristol Myers Squibb, AstraZeneca, Kyowa Kirin |
| Key Drivers | • Rising clinical trials for the Breast Cancer Therapeutics Market |
| Market Opportunities | • Rise in the technological advancement in the healthcare sector specially related to the imaging sector. |
Ans : The Breast Cancer Therapeutics Market size was valued at USD 30.22 billion in 2022 and is expected to reach at USD 79.77 billion by 2030, and grow at a CAGR of 12.9% over the forecast period of 2023-2030.
Ans : Inequalities in access to breast cancer therapies continue to be problematic, especially for underserved and low-income groups.
Ans : Market is divided in three segments by Therapy Type, by Cancer Type and by Distribution Channel.
Ans : North America will be the region which has the highest growth rate because of The healthcare systems in North America, especially in the United States
Ans : Chemotherapy and radiation therapy are two common breast cancer therapies that can have serious side effects that lower a patient's quality of life.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Breast Cancer Therapeutics Market Segmentation By Therapy Type
8.1 Targeted Therapy
8.2 Hormonal Therapy
8.3 Chemotherapy
8.4 Immunotherapy
9. Breast Cancer Therapeutics Market Segmentation By Cancer Type
9.1 Hormone Receptor
9.2 HER2+
10. Breast Cancer Therapeutics Market Segmentation By Distribution Channel
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Online Pharmacies
10.4 Others
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Breast Cancer Therapeutics Market by country
11.2.2North America Breast Cancer Therapeutics Market by Therapy Type
11.2.3 North America Breast Cancer Therapeutics Market by Cancer Type
11.2.4 North America Breast Cancer Therapeutics Market by Distribution Channel
11.2.5 USA
11.2.5.1 USA Breast Cancer Therapeutics Market by Therapy Type
11.2.5.3 USA Breast Cancer Therapeutics Market by Cancer Type
11.2.5.4 USA Breast Cancer Therapeutics Market by Distribution Channel
11.2.6 Canada
11.2.6.1 Canada Breast Cancer Therapeutics Market by Therapy Type
11.2.6.3 Canada Breast Cancer Therapeutics Market by Cancer Type
11.2.6.4 Canada Breast Cancer Therapeutics Market by Distribution Channel
11.2.7 Mexico
11.2.7.1 Mexico Breast Cancer Therapeutics Market by Therapy Type
11.2.7.3 Mexico Breast Cancer Therapeutics Market by Cancer Type
11.2.7.4 Mexico Breast Cancer Therapeutics Market by Distribution Channel
11.3 Europe
11.3.1 Europe Breast Cancer Therapeutics Market by country
1.3.3.2 Europe Breast Cancer Therapeutics Market by Therapy Type
11.3.3 Europe Breast Cancer Therapeutics Market by Cancer Type
11.3.4 Europe Breast Cancer Therapeutics Market by Distribution Channel
11.3.5 Germany
11.3.5.1 Germany Breast Cancer Therapeutics Market by Therapy Type
11.3.5.2 Germany Breast Cancer Therapeutics Market by Cancer Type
11.3.5.3 Germany Breast Cancer Therapeutics Market by Distribution Channel
11.3.6 UK
11.3.6.1 UK Breast Cancer Therapeutics Market by Therapy Type
11.3.6.2 UK Breast Cancer Therapeutics Market by Cancer Type
11.3.6.3 UK Breast Cancer Therapeutics Market by Distribution Channel
11.3.7 France
11.3.7.1 France Breast Cancer Therapeutics Market by Therapy Type
11.3.7.2 France Breast Cancer Therapeutics Market by Cancer Type
11.3.7.3 France Breast Cancer Therapeutics Market by Distribution Channel
11.3.8 Italy
11.3.8.1 Italy Breast Cancer Therapeutics Market by Therapy Type
11.3.8.2 Italy Breast Cancer Therapeutics Market by Cancer Type
11.3.8.3 Italy Breast Cancer Therapeutics Market by Distribution Channel
11.3.9 Spain
11.3.9.1 Spain Breast Cancer Therapeutics Market by Therapy Type
11.3.9.2 Spain Breast Cancer Therapeutics Market by Cancer Type
11.3.9.3 Spain Breast Cancer Therapeutics Market by Distribution Channel
11.3.10 The Netherlands
11.3.10.1 Netherlands Breast Cancer Therapeutics Market by Therapy Type
11.3.10.2 Netherlands Breast Cancer Therapeutics Market by Cancer Type
11.3.10.3 Netherlands Breast Cancer Therapeutics Market by Distribution Channel
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Breast Cancer Therapeutics Market by Therapy Type
11.3.11.2 Rest of Europe Breast Cancer Therapeutics Market by Cancer Type
11.3.11.3 Rest of Europe Breast Cancer Therapeutics Market by Distribution Channel
11.4 Asia-Pacific
11.4.1 Asia Pacific Breast Cancer Therapeutics Market by country
11.4.2 Asia Pacific Breast Cancer Therapeutics Market by Therapy Type
11.4.3 Asia Pacific Breast Cancer Therapeutics Market by Cancer Type
11.4.4 Asia Pacific Breast Cancer Therapeutics Market by Distribution Channel
11.4.5 Japan
11.4.5.1 Japan Breast Cancer Therapeutics Market by Therapy Type
11.4.5.2 Japan Breast Cancer Therapeutics Market by Cancer Type
11.4.5.3 Japan Breast Cancer Therapeutics Market by Distribution Channel
11.4.6 South Korea
11.4.6.1 South Korea Breast Cancer Therapeutics Market by Therapy Type
11.4.6.2 South Korea Breast Cancer Therapeutics Market by Cancer Type
11.4.6.3 South Korea Breast Cancer Therapeutics Market by Distribution Channel
11.4.7 China
11.4.7.1 China Breast Cancer Therapeutics Market by Therapy Type
11.4.7.2 China Breast Cancer Therapeutics Market by Cancer Type
11.4.7.3 China Breast Cancer Therapeutics Market by Distribution Channel
11.4.8 India
11.4.8.1 India Breast Cancer Therapeutics Market by Therapy Type
11.4.8.2 India Breast Cancer Therapeutics Market by Cancer Type
11.4.8.3 India Breast Cancer Therapeutics Market by Distribution Channel
11.4.9 Australia
11.4.9.1 Australia Breast Cancer Therapeutics Market by Therapy Type
11.4.9.2 Australia Breast Cancer Therapeutics Market by Cancer Type
11.4.9.3 Australia Breast Cancer Therapeutics Market by Distribution Channel
11.4.10 Rest of Asia-Pacific
11.4.10.1 APAC Breast Cancer Therapeutics Market by Therapy Type
11.4.10.2 APAC Breast Cancer Therapeutics Market by Cancer Type
11.4.10.3 APAC Breast Cancer Therapeutics Market by Distribution Channel
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Breast Cancer Therapeutics Market by country
11.5.2 The Middle East & Africa Breast Cancer Therapeutics Market by Therapy Type
11.5.3 The Middle East & Africa Breast Cancer Therapeutics Market by Cancer Type
11.5.4 The Middle East & Africa Breast Cancer Therapeutics Market by Distribution Channel
11.5.6 Israel
11.5.6.1 Israel Breast Cancer Therapeutics Market by Therapy Type
11.5.6.2 Israel Breast Cancer Therapeutics Market by Cancer Type
11.5.6.3 Israel Breast Cancer Therapeutics Market by Distribution Channel
11.5.6 UAE
11.5.6.1 UAE Breast Cancer Therapeutics Market by Therapy Type
11.5.6.2 UAE Breast Cancer Therapeutics Market by Cancer Type
11.5.6.3 UAE Breast Cancer Therapeutics Market by Distribution Channel
11.5.7 South Africa
11.5.7.1 South Africa Breast Cancer Therapeutics Market by Therapy Type
11.5.7.2 South Africa Breast Cancer Therapeutics Market by Cancer Type
11.5.7.3 South Africa Breast Cancer Therapeutics Market by Distribution Channel
11.5.8 Rest of Middle East & Africa
11.5.8.1 Rest of Middle East & Asia Breast Cancer Therapeutics Market by Therapy Type
11.5.8.2 Rest of Middle East & Asia Breast Cancer Therapeutics Market Phase
11.5.8.3 Rest of Middle East & Asia Breast Cancer Therapeutics Market by Distribution Channel
11.6 Latin America
11.6.1 Latin America Breast Cancer Therapeutics Market by country
11.6.2 Latin America Breast Cancer Therapeutics Market by Therapy Type
11.6.3 Latin America Breast Cancer Therapeutics Market by Cancer Type
11.6.4 Latin America Breast Cancer Therapeutics Market by Distribution Channel
11.6.5 Brazil
11.6.5.1 Brazil Breast Cancer Therapeutics Market by Therapy Type
11.6.5.2 Brazil Breast Cancer Therapeutics Market by Cancer Type
11.6.2.3 Brazil Breast Cancer Therapeutics Market by Distribution Channel
11.6.6 Argentina
11.6.6.1 Argentina Breast Cancer Therapeutics Market by Therapy Type
11.6.6.2 Argentina Breast Cancer Therapeutics Market by Cancer Type
11.6.6.3 Argentina Breast Cancer Therapeutics Market by Distribution Channel
11.6.7 Rest of Latin America
11.6.7.1 Rest of Latin America Breast Cancer Therapeutics Market by Therapy Type
11.6.7.2 Rest of Latin America Breast Cancer Therapeutics Market by Cancer Type
11.6.7.3 Rest of Latin America Breast Cancer Therapeutics Market by Distribution Channel
12. Company Profile
12.1 Pfizer
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Product /Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Eli Lilly and Company
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Product /Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Novartis Ag
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Product /Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Sanofi
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Product /Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Eisai Co
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Product /Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Merck & Co
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Product /Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Bristol Myers Squibb
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Product /Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 AstraZeneca
12.8.1 Market Overview
12.8.2 Financials
12.8.3 Product /Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Kyowa Kirin
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Product /Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Others
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Product /Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
14. Use cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The 3D Cone Beam CT Systems (CBCT) Market assessed at USD 699.33 Million in the year 2022, is projected to arrive at a size of USD 1.40 Billion by 2030, growing at a CAGR of 9.1% over the period 2023-2030.
The Scanning electron microscopes Market Size was valued at USD 4.12 billion in 2022 and is expected to reach USD 8.16 billion by 2030, and grow at a CAGR of 8.9% over the forecast period 2023-2030.
The Dry Age-Related Macular Degeneration Market Size was valued at USD 11.12 billion in 2022 and is expected to reach USD 20.92 billion by 2030 and grow at a CAGR of 8.22% over the forecast period 2023-2030.
The Breast Imaging Market size was estimated USD 0.17 billion in 2022 and is expected to reach USD 0.28 billion by 2030 at a CAGR of 6.8% during the forecast period of 2023-2030.
In 2022, The Asthma Treatment Market size amounted to USD 20.4 Billion & is estimated to reach USD 29.45 Billion by 2030 and increase at a compound annual growth rate of 4.7% between 2023 and 2030.
The Clinical Risk Grouping Solutions Market Size was valued at USD 640 million in 2022, and is expected to reach USD 1890 million by 2030, and grow at a CAGR of 14.5% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
